---
title: "全球首款六價輪狀病毒疫苗獲批上市"
description: "國藥集團中國生物武漢生物製品研究所研製的口服六價重配輪狀病毒減毒活疫苗（商品名：武生兒輪寶®）已獲得國家藥品監督管理局批准上市。這是全球首款六價輪狀病毒疫苗，主要用於預防嬰幼兒急性胃腸炎。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/254143820.md"
published_at: "2025-08-22T10:30:05.000Z"
---

# 全球首款六價輪狀病毒疫苗獲批上市

> 國藥集團中國生物武漢生物製品研究所研製的口服六價重配輪狀病毒減毒活疫苗（商品名：武生兒輪寶®）已獲得國家藥品監督管理局批准上市。這是全球首款六價輪狀病毒疫苗，主要用於預防嬰幼兒急性胃腸炎。

近日，國藥集團中國生物武漢生物製品研究所研製的口服六價重配輪狀病毒減毒活疫苗（Vero 細胞）（商品名：武生兒輪寶®）正式獲得國家藥品監督管理局批准上市。該產品是全球首款、價次最高的輪狀病毒疫苗，為我國預防用生物製品 1 類新藥，主要用於預防輪狀病毒引起的嬰幼兒急性胃腸炎。

### Related Stocks

- [01099.HK - 國藥控股](https://longbridge.com/zh-HK/quote/01099.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| A Look At CK Hutchison Holdings (SEHK:1) Valuation After Recent Share Price Momentum | CK Hutchison Holdings (SEHK:1) has gained investor attention due to a strong share price performance, with a 19.3% retur | [Link](https://longbridge.com/zh-HK/news/276191173.md) |
| Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | [Link](https://longbridge.com/zh-HK/news/276056763.md) |
| Standard Chartered PLC (OTCMKTS:SCBFF) Sees Significant Growth in Short Interest | Standard Chartered PLC (OTCMKTS:SCBFF) experienced a significant increase in short interest, rising 21.1% to 210,583 sha | [Link](https://longbridge.com/zh-HK/news/276119010.md) |
| Will China Literature Turn The Page? | China Literature Ltd. expects a net loss of up to 850 million yuan for last year, primarily due to a 1.8 billion yuan go | [Link](https://longbridge.com/zh-HK/news/276113491.md) |
| Berkshire Hathaway discloses investment in New York Times | Berkshire Hathaway has disclosed a new investment in the New York Times, reentering a sector it left in 2020. The compan | [Link](https://longbridge.com/zh-HK/news/276173033.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。